Coinfection (HIV/MAC)

Withdrawal of anti-MAC therapy seems safe for certain patients

Published in TB and Outbreaks Week, May 20th, 2003

According to a report from the AIDS Clinical Trial Group 393 study team, anti-Mycobacterium avium complex (MAC) therapy can be safely discontinued in patients who've had at least a year of macrolide-based treatment and have an immunologic response on highly active antiretroviral therapy (HAART).

For this study, "eligible subjects had received macrolide-based therapy for least 12 months, were asymptomatic for MAC, had received HAART for at least 16 weeks, and had CD4+ T-cell counts >100 cells/microL. Forty-eight subjects were enrolled, with a median CD4+ T-cell count of 240 cells/microL at the time of discontinuation of MAC therapy," said J.A. Aberg of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2003-05-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry